IN
IN8bio, Inc.
INAB · NASDAQ
$1.40 +5.26% (+$0.07)
1M +27.27%
Market Cap $13.4M
P/E Ratio -
Div. Yield -
ROE 91.18%
Bulios Fair Price
$0.74
47.1% downside
Current Price
$1.4
Undervalued Fair Value Overvalued
According to Bulios Fair Price, INAB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.73x
P/E N/A
EV/EBITDA N/A
Growth
60 /100
Stable Book val. growth 6.63%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 91.74%
ROE 91.18%
Asset turnover 0.00x
Debt
100 /100
Low Debt/Equity 0.12x
Current ratio 8.21x
Int. coverage N/A
Stability
10 /100
Unstable Beta 0.30x
EPS volatility 412.13%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INAB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
William T.
Employees
18
Headquarters
New York City
Upcoming events
05 NOV
Earnings
Upcoming earnings report